Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
Authors: Ioannidis JP,  Rosenberg PS,  Goedert JJ,  Ashton LJ,  Benfield TL,  Buchbinder SP,  Coutinho RA,  Eugen-Olsen J,  Gallart T,  Katzenstein TL,  Kostrikis LG,  Kuipers H,  Louie LG,  Mallal SA,  Margolick JB,  Martinez OP,  Meyer L,  Michael NL,  Operskalski E,  Pantaleo G,  Rizzardi GP,  Schuitemaker H,  Sheppard HW,  Stewart GJ,  Theodorou ID,  Ullum H,  Vicenzi E,  Vlahov D,  Wilkinson D,  Workman C,  Zagury JF,  O'Brien TR,  International Meta-Analysis of HIV Host Genetics
Journal: Ann Intern Med
Date: 2001 Nov 6
Branches: BB, IIB
PubMed ID: 11694103
PMC ID: not available
Abstract: BACKGROUND: Studies relating certain chemokine and chemokine receptor gene alleles with the outcome of HIV-1 infection have yielded inconsistent results. OBJECTIVE: To examine postulated associations of genetic alleles with HIV-1 disease progression. DESIGN: Meta-analysis of individual-patient data. SETTING: 19 prospective cohort studies and case-control studies from the United States, Europe, and Australia. PATIENTS: Patients with HIV-1 infection who were of European or African descent. MEASUREMENTS: Time to AIDS, death, and death after AIDS and HIV-1 RNA level at study entry or soon after seroconversion. Data were combined with fixed-effects and random-effects models. RESULTS: Both the CCR5-Delta32 and CCR2-64I alleles were associated with a decreased risk for progression to AIDS (relative hazard among seroconverters, 0.74 and 0.76, respectively; P = 0.01 for both), a decreased risk for death (relative hazard among seroconverters, 0.64 and 0.74; P < 0.05 for both), and lower HIV-1 RNA levels after seroconversion (difference, -0.18 log(10) copies/mL and -0.14 log(10) copies/mL; P < 0.05 for both). Having the CCR5-Delta32 or CCR2-64I allele had no clear protective effect on the risk for death after development of AIDS. The results were consistent between seroconverters and seroprevalent patients. In contrast, SDF-1 3'A homozygotes showed no decreased risk for AIDS (relative hazard for seroconverters and seroprevalent patients, 0.99 and 1.03, respectively), death (relative hazard, 0.97 and 1.00), or death after development of AIDS (relative hazard, 0.81 and 0.97; P > 0.5 for all). CONCLUSIONS: The CCR5-Delta32 and CCR2-64I alleles had a strong protective effect on progression of HIV-1 infection, but SDF-1 3'A homozygosity carried no such protection.